During the past decade, Queen Elizabeth conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Queen Elizabeth" are "Coronary Artery Disease" (2 trials), "Coronary Disease" (1 trials) and "Coronary Restenosis" (1 trials). Many other conditions were trialed in "Queen Elizabeth" in a lesser frequency.

Most popular intervention types in "Queen Elizabeth" are "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)" (1 trials), "XIENCE V® Everolimus Eluting Coronary Stent" (1 trials) and "XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Queen Elizabeth" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Queen Elizabeth". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Queen Elizabeth, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Queen Elizabeth, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".